Union Budget 2024 benefits pharma, healthcare by exempting AstraZeneca's cancer drugs Trastuzumab Deruxtecan, Osimertinib, Durvalumab, boosting stock 13%. Reduces duties on x-ray tubes, flat panel detectors for medical x-ray machines, enhancing domestic capacity. Increases PLI scheme allocation to Rs 2,143 crore, aiding cancer patients.
